"At UCSF Health, we're taking every precaution to keep you safe and healthy during the COVID-19 pandemic. For our outpatients, we offer video visits and virtual care for hundreds of conditions as well as for primary care, mental health services, medication monitoring and more. In our hospitals, we test every patient admitted and before most procedures. Our staff wears face masks and practices rigorous hand hygiene, as well as many other methods of infection prevention. Before entering your room, they'll make sure you're masked and (in UCSF Benioff Children's Hospitals) that your child age 2+ is masked. If you're planning to visit someone in the hospital, be sure to check our COVID-19 visitor restrictions before going."

During the past decade, Multiple Sclerosis Center at UCSF conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 7 clinical trials were completed, i.e. on average, 87.5% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Multiple Sclerosis Center at UCSF" #1 sponsor was "Celgene" with 4 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Genzyme, a Sanofi Company" with 2 trials sponsored, "University of California, San Francisco" with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Multiple Sclerosis Center at UCSF" #1 collaborator was "National Multiple Sclerosis Society" with 1 trials as a collaborator and "Teva Neuroscience, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Multiple Sclerosis Center at UCSF" are "Multiple Sclerosis" (8 trials), "Gaucher Disease, Type 1" (2 trials), "Multiple Sclerosis, Relapsing-Remitting" (2 trials), "Relapsing Multiple Sclerosis" (1 trials) and "Relapsing Remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Multiple Sclerosis Center at UCSF" in a lesser frequency.

Most popular intervention types in "Multiple Sclerosis Center at UCSF" are "Drug" (13 trials), "Device" (1 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Eliglustat tartrate" (2 trials), "Interferon beta-1a" (2 trials), "Ocrelizumab" (2 trials) and "Ozanimod" (2 trials). Other intervention names were less common.

The vast majority of trials in "Multiple Sclerosis Center at UCSF" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Multiple Sclerosis Center at UCSF". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Multiple Sclerosis Center at UCSF, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Multiple Sclerosis Center at UCSF, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".